Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study.
Absorptiometry, Photon
Adult
Anti-HIV Agents
/ therapeutic use
Bone Density
Calcaneus
/ diagnostic imaging
Creatinine
/ urine
Cross-Sectional Studies
Female
HIV Infections
/ complications
Humans
Kidney Diseases
/ complications
Kidney Tubules, Proximal
Male
Pilot Projects
Retinol-Binding Proteins
/ urine
Uganda
Ultrasonography
bone metabolic diseases
HIV
calcaneal ultrasound
resource-limited setting
tubular impairment
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
29 06 2020
29 06 2020
Historique:
received:
13
01
2020
accepted:
27
02
2020
pubmed:
1
3
2020
medline:
16
2
2021
entrez:
1
3
2020
Statut:
ppublish
Résumé
Data on bone health and renal impairment in people with human immunodeficiency virus (HIV) in resource-limited settings are limited. The primary aim of this study was to investigate the potential role of calcaneal quantitative ultrasonography (QUS) in predicting bone mineral density (BMD) reduction in a population of Ugandan HIV-infected individuals receiving long-term antiretroviral therapy; the secondary end point was to assess the prevalence of proximal tubular dysfunction and the correlation between elevated urinary retinol-binding protein-urinary creatinine ratio (uRBP/uCr) and reduced BMD. We conducted a cross-sectional study at the Infectious Diseases Institute, Kampala, Uganda. We included 101 HIV-infected adults who had been receiving continuous antiretroviral therapy for ≥10 years and had undergone dual-energy x-ray absorptiometry (DXA) during the previous 12 months. All patients underwent calcaneal QUS evaluation and urine sample collection. DXA BMD measurements were significantly associated (P < .01) with calcaneal speed of sound, broadband ultrasound attenuation, and QUS index. Forty-seven individuals (47%) had abnormal uRBP/uCr values. A significant inverse correlation was observed between uRBP/uCr and DXA T scores (lumbar [P = .03], femoral neck [P < .001], and total hip [P = .002]). Calcaneal QUS results showed a moderate correlation with DXA outputs. The identified high prevalence of subclinical tubular impairment also highlights the importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resource-limited settings.
Sections du résumé
BACKGROUND
Data on bone health and renal impairment in people with human immunodeficiency virus (HIV) in resource-limited settings are limited. The primary aim of this study was to investigate the potential role of calcaneal quantitative ultrasonography (QUS) in predicting bone mineral density (BMD) reduction in a population of Ugandan HIV-infected individuals receiving long-term antiretroviral therapy; the secondary end point was to assess the prevalence of proximal tubular dysfunction and the correlation between elevated urinary retinol-binding protein-urinary creatinine ratio (uRBP/uCr) and reduced BMD.
METHODS
We conducted a cross-sectional study at the Infectious Diseases Institute, Kampala, Uganda. We included 101 HIV-infected adults who had been receiving continuous antiretroviral therapy for ≥10 years and had undergone dual-energy x-ray absorptiometry (DXA) during the previous 12 months. All patients underwent calcaneal QUS evaluation and urine sample collection.
RESULTS
DXA BMD measurements were significantly associated (P < .01) with calcaneal speed of sound, broadband ultrasound attenuation, and QUS index. Forty-seven individuals (47%) had abnormal uRBP/uCr values. A significant inverse correlation was observed between uRBP/uCr and DXA T scores (lumbar [P = .03], femoral neck [P < .001], and total hip [P = .002]).
CONCLUSIONS
Calcaneal QUS results showed a moderate correlation with DXA outputs. The identified high prevalence of subclinical tubular impairment also highlights the importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resource-limited settings.
Identifiants
pubmed: 32112093
pii: 5766432
doi: 10.1093/infdis/jiaa088
pmc: PMC7323491
doi:
Substances chimiques
Anti-HIV Agents
0
Retinol-Binding Proteins
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-272Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
PLoS One. 2017 Nov 8;12(11):e0186686
pubmed: 29117238
AIDS. 2015 Sep 10;29(14):1785-1792
pubmed: 26372384
Clin Infect Dis. 2003 Feb 15;36(4):482-90
pubmed: 12567307
AIDS. 2016 Mar 27;30(6):915-20
pubmed: 26636928
J Infect Dis. 2015 Oct 15;212(8):1241-9
pubmed: 25948863
Pharmacogenomics J. 2016 Nov;16(6):514-518
pubmed: 26440731
AIDS. 2009 Mar 27;23(6):689-96
pubmed: 19262355
AIDS. 2009 Jul 17;23(11):1297-310
pubmed: 19550284
J Int AIDS Soc. 2017 Apr 10;20(1):21317
pubmed: 28406595
Clin Infect Dis. 2014 May;58(10):1473-80
pubmed: 24585558
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):161-8
pubmed: 25072617
PLoS One. 2015 May 28;10(5):e0124741
pubmed: 26020949
Am J Kidney Dis. 2009 Dec;54(6):1034-42
pubmed: 19783343
Lancet. 1996 Aug 24;348(9026):511-4
pubmed: 8757153
Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32
pubmed: 28761958
Arch Intern Med. 1997 Mar 24;157(6):629-34
pubmed: 9080917
J Infect Dis. 2011 Jun 15;203(12):1791-801
pubmed: 21606537
AIDS. 2019 Jul 15;33(9):1455-1465
pubmed: 30932951
AIDS. 2013 Sep 24;27(15):2403-11
pubmed: 23921615
Curr Opin HIV AIDS. 2016 May;11(3):306-25
pubmed: 27023284
Lancet. 2013 Jun 15;381(9883):2091-9
pubmed: 23769235
Osteoporos Int. 2014 Sep;25(9):2263-9
pubmed: 25056799
Calcif Tissue Int. 2012 Jan;90(1):1-13
pubmed: 22057815
PLoS One. 2012;7(2):e31726
pubmed: 22359621
Lancet. 2019 Jan 12;393(10167):143-155
pubmed: 30420123
Lancet. 2004 Jan 17;363(9404):197-202
pubmed: 14738792
AIDS. 2006 Nov 14;20(17):2165-74
pubmed: 17086056
AIDS. 2001 Jul 6;15(10):1275-80
pubmed: 11426072
J Infect. 2018 Jun;76(6):515-521
pubmed: 29702139
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):588-92
pubmed: 19502989
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Osteoporos Int. 2001 Dec;12(12):989-95
pubmed: 11846333
PLoS One. 2019 Oct 17;14(10):e0222225
pubmed: 31622347
Braz J Infect Dis. 2017 Nov - Dec;21(6):581-586
pubmed: 28950107
J Acquir Immune Defic Syndr. 2010 Sep;55(1):49-57
pubmed: 20431394
AIDS. 2007 Jun 19;21(10):1273-81
pubmed: 17545703
Clin Infect Dis. 2010 Oct 15;51(8):937-46
pubmed: 20839968
AIDS. 2009 Apr 27;23(7):817-24
pubmed: 19363330
J Virus Erad. 2018 Apr 1;4(2):72-79
pubmed: 29682298
PLoS One. 2018 Nov 1;13(11):e0206796
pubmed: 30383836
New Microbiol. 2015 Jul;38(3):345-56
pubmed: 26147144
Clin Infect Dis. 2010 Oct 15;51(8):963-72
pubmed: 20828304